In a parallel effort targeting hormone-responsive cancers, Zhang et al. synthesized a tamoxifen–ZnPc conjugate to integrate PDT with estrogen receptor (ER)-targeted endocrine therapy. This evidence concerns the gene ESR1 and cancer.